132 related articles for article (PubMed ID: 35251316)
1. Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models.
Lim SM; Yang SD; Lim S; Heo SG; Daniel S; Markovets A; Minoo R; Pyo KH; Yun MR; Hong MH; Kim HR; Cho BC
Ther Adv Med Oncol; 2022; 14():17588359221079125. PubMed ID: 35251316
[TBL] [Abstract][Full Text] [Related]
2. Targeting
Aboubakar Nana F; Ocak S
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575554
[TBL] [Abstract][Full Text] [Related]
3. The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Huang WC; Yadav VK; Cheng WH; Wang CH; Hsieh MS; Huang TY; Lin SF; Yeh CT; Kuo KT
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885115
[TBL] [Abstract][Full Text] [Related]
4. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR
Park HR; Kim TM; Lee Y; Kim S; Park S; Ju YS; Kim M; Keam B; Jeon YK; Kim DW; Heo DS
J Thorac Oncol; 2021 Nov; 16(11):1859-1871. PubMed ID: 34242789
[TBL] [Abstract][Full Text] [Related]
5. CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib.
Kato R; Hayashi H; Sakai K; Suzuki S; Haratani K; Takahama T; Tanizaki J; Nonagase Y; Tanaka K; Yoshida T; Takeda M; Yonesaka K; Kaneda H; Nishio K; Nakagawa K
Int J Clin Oncol; 2021 Sep; 26(9):1628-1639. PubMed ID: 34117553
[TBL] [Abstract][Full Text] [Related]
6. Novel Resistance Mechanisms to Osimertinib Analysed by Whole-Exome Sequencing in Non-Small Cell Lung Cancer.
Wu Z; Zhao W; Yang Z; Wang YM; Dai Y; Chen LA
Cancer Manag Res; 2021; 13():2025-2032. PubMed ID: 33658860
[TBL] [Abstract][Full Text] [Related]
7.
Zheng Q; Huang Y; Zhao H; Yang Y; Hong S; Hou X; Zhao Y; Ma Y; Zhou T; Zhang Y; Fang W; Zhang L
Transl Lung Cancer Res; 2020 Jun; 9(3):471-483. PubMed ID: 32676311
[TBL] [Abstract][Full Text] [Related]
8. Feiyiliu Mixture sensitizes EGFR
Shi J; Hao S; Liu X; Li Y; Zheng X
Front Pharmacol; 2023; 14():1093017. PubMed ID: 36744262
[No Abstract] [Full Text] [Related]
9. ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib.
Romero A; Serna-Blasco R; Alfaro C; Sánchez-Herrero E; Barquín M; Turpin MC; Chico S; Sanz-Moreno S; Rodrigez-Festa A; Laza-Briviesca R; Cruz-Bermudez A; Calvo V; Royuela A; Provencio M
Transl Lung Cancer Res; 2020 Jun; 9(3):532-540. PubMed ID: 32676317
[TBL] [Abstract][Full Text] [Related]
10. Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report.
Jiang Y; Zhang J; Jiang X; Cheng L; Liao X; Li Y; Zhang M; Chen R; Yin T
Ann Palliat Med; 2021 Jun; 10(6):7051-7056. PubMed ID: 33548986
[TBL] [Abstract][Full Text] [Related]
11. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
12. EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome.
Vendrell JA; Quantin X; Aussel A; Solassol I; Serre I; Solassol J
Transl Lung Cancer Res; 2021 Nov; 10(11):4084-4094. PubMed ID: 35004240
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy.
Jóri B; Schatz S; Kaller L; Kah B; Roeper J; Ramdani HO; Diehl L; Hoffknecht P; Grohé C; Griesinger F; Tiemann M; Heukamp LC; Falk M
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201252
[TBL] [Abstract][Full Text] [Related]
14. Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis
Zhou R; Song L; Zhang W; Shao L; Li X; Li X
Onco Targets Ther; 2021; 14():2847-2851. PubMed ID: 33958875
[TBL] [Abstract][Full Text] [Related]
15. First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments.
Nie N; Li J; Zhang J; Dai J; Liu Z; Ding Z; Wang Y; Zhu M; Hu C; Han R; Tang H; Li L; He Y
Clin Med Insights Oncol; 2022; 16():11795549221134735. PubMed ID: 36387609
[TBL] [Abstract][Full Text] [Related]
16. Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance.
Maity TK; Kim EY; Cultraro CM; Venugopalan A; Khare L; Poddutoori R; Marappan S; Syed SD; Telford WG; Samajdar S; Ramachandra M; Guha U
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190191
[TBL] [Abstract][Full Text] [Related]
17. MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib.
Ninomiya K; Ohashi K; Makimoto G; Tomida S; Higo H; Kayatani H; Ninomiya T; Kubo T; Ichihara E; Hotta K; Tabata M; Maeda Y; Kiura K
Sci Rep; 2018 Jan; 8(1):1955. PubMed ID: 29386539
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
[TBL] [Abstract][Full Text] [Related]
19. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M,
Chang Y; Liu S; Jiang Y; Hua L; Wen L
Respir Med Case Rep; 2022; 36():101582. PubMed ID: 35106279
[TBL] [Abstract][Full Text] [Related]
20. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.
Guibert N; Hu Y; Feeney N; Kuang Y; Plagnol V; Jones G; Howarth K; Beeler JF; Paweletz CP; Oxnard GR
Ann Oncol; 2018 Apr; 29(4):1049-1055. PubMed ID: 29325035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
